Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is well-positioned to capitalize on a rebound in biotech funding, with a focus on protein sciences and diagnostic and genomics markets. The company also has a strong presence globally, with exposure to key markets such as the US, Europe, and Asia-Pacific. Despite some near-term challenges, including the COVID-19 pandemic and a loss of GMP reagent revenue, Bio-Techne remains focused on self-help opportunities, including the recently announced brand consolidation. The upcoming acquisition of Wilson Wolf could be a significant growth driver for the company, with potential to increase its structural growth and exposure to the cell therapy market. While risks such as potential delays in end market recovery and acquisition risk exist, overall, Bio-Techne's strong product offerings, global operations, and strategic focus make it well-positioned for long-term success in the life sciences industry.

Bears say

Bio-Techne is at risk for a decrease in valuation if the proposed acquisition of Wilson Wolf does not close, the end market recovery for the life science tools industry is delayed or does not occur, and the company experiences share loss due to potential competition and advancements in cell therapy or AI technology. However, the company has a strong track record in making successful acquisitions and is positioning itself for future growth through self-help initiatives. Our downside price target of $38 reflects potential challenges in growth and multiple compression, but we believe the company has strong potential for rebound and profitability with its leverage to the biotech funding rebound and transformative acquisition of Wilson Wolf.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.